Key facts
- It has raised $4.5M; the latest was Seed Round ($1.6M) in May 2025.
- Notable investors include Business Finland, Force Ten Partners, Nordic Science Investments, Outpatient Care Research Foundation.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for RNatives
- ·The full record, as it builds
Funding rounds
No funding rounds for RNatives are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About RNatives
Operator of a biotechnology platform designed to create precision RNA-based gene-regulating therapies for the treatment of serious diseases. The company offers an RNAIntel platform that identifies small non-coding RNAs to regulate gene expression, enabling patients with ocular and metabolic diseases, as well as cancer, to access targeted and effective therapeutic options.
- Sector
- Healthcare
- HQ
- Kuopio, Finland
- Founded
- 2020
- Employees
- 10
- Website
- rnatives.com/
- Ownership
- Privately Held (backing)
RNatives doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in RNatives shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on RNatives in its N-PORT filings yet. We sweep new filings monthly.